Calidi Biotherapeutics, Inc

Contributing Author

Recent Articles by Calidi Biotherapeutics, Inc

Apr-20	Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 CLDI -9.02% GlobeNewswire
Apr-15	Calidi Biotherapeutics Announces Participation in RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms CLDI GlobeNewswire
Apr-14	Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavik, Iceland on April 28th Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy CLDI GlobeNewswire
Apr-07	Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy CLDI GlobeNewswire
Apr-02	Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 CLDI GlobeNewswire
Apr-01	Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 CLDI GlobeNewswire
Mar-27	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights CLDI -11.67% CLDI GlobeNewswire
Mar-24	Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials CLDI GlobeNewswire
Mar-12	Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing CLDI GlobeNewswire
Mar-09	Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option CLDI GlobeNewswire
Mar-06	Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering CLDI -53.14% GlobeNewswire
Mar-05	Calidi Biotherapeutics Announces Proposed Public Offering CLDI GlobeNewswire
Feb-20	Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference CLDI +7.97% GlobeNewswire
Feb-12	Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference CLDI -6.89% GlobeNewswire
Jan-28	Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 CLDI GlobeNewswire
Nov-17	Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 CLDI GlobeNewswire
Nov-13	Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights CLDI GlobeNewswire
Nov-10	Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC CLDI GlobeNewswire
Nov-04	Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting CLDI GlobeNewswire
Oct-30	Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting CLDI +6.04% GlobeNewswire
Oct-22	Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine CLDI -5.26% GlobeNewswire
Sep-29	Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston CLDI GlobeNewswire
Sep-02	Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference CLDI GlobeNewswire
Aug-21	Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option CLDI GlobeNewswire
Aug-20	Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering CLDI -42.67% GlobeNewswire
Aug-08	Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights CLDI -13.02% GlobeNewswire
Jul-29	Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma CLDI +14.94% GlobeNewswire
Jul-25	Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 CLDI -24.71% CLDI -5.43% GlobeNewswire
Jul-22	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24 CLDI GlobeNewswire
Jul-10	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment CLDI +42.57% GlobeNewswire
Jul-09	Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds CLDI +108.96% GlobeNewswire
Jul-08	Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment CLDI +39.47% GlobeNewswire
Jun-27	Calidi Biotherapeutics Announces Shareholder Letter from CEO CLDI GlobeNewswire
Jun-02	Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting CLDI GlobeNewswire
May-14	Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights CLDI -8.47% GlobeNewswire

Calidi Biotherapeutics, Inc

Recent Articles by Calidi Biotherapeutics, Inc

Upgrade your Finviz experience